Cost-effectiveness analysis of eight first-line treatments for metastatic hormone-sensitive prostate cancer in China
Abiraterone plus ADT was likely to be cost-effective for mHSPC treatment at a WTP threshold of three-time <i>per capita</i> GDP per QALY.
Authors
- Huanyu Ni (ORCID: https://orcid.org/0000-0002-6112-7799)
- Youli Xi
- Ye Wang (ORCID: https://orcid.org/0009-0009-9048-3838)
- Han Zhou (ORCID: https://orcid.org/0000-0002-8067-4878)
- Hu Jian (ORCID: https://orcid.org/0000-0003-3611-7043)
Institutions
- Sir Run Run Shaw Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Zhejiang University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3389/fphar.2025.1684966
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jiangsu Pharmaceutical Association